[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345018-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345018-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evidence-for-the-monitoring-of-minimal-residual-disease-dynamics-to-guide-clinical-practice-in-patients-with-multiple-myeloma","Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma","","Multiple myeloma (MM) is a heterogeneous, still incurable cancer in which minimal residual disease (MRD) clonal cells after therapy drive relapse and treatment failure. MRD status is dynamic: sustained MRD negativity predicts markedly improved survival, while loss of negativity signals progression. Although MRD dynamics are being studied for real-world practice, implementing MRD-dynamics monitoring and MRD-guided therapeutic decisions in everyday MM care remains challenging and requires resolution of key concerns. This review synthesizes prognostic value, evidence for MRD-guided decisions, and implementation barriers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evidence-for-the-monitoring-of-minimal-residual-disease-dynamics-to-guide-clinical-practice-in-patients-with-multiple-myeloma/345018/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evidence-for-the-monitoring-of-minimal-residual-disease-dynamics-to-guide-clinical-practice-in-patients-with-multiple-myeloma/345018.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is minimal residual disease (MRD) important in multiple myeloma?","Question",{"text":63,"@type":64},"After treatment, residual myeloma clonal cells (MRD) are linked to relapse and treatment failure. MRD is described as a strong surrogate marker of survival and has important prognostic value in MM management.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do MRD dynamics affect clinical interpretation over time?",{"text":68,"@type":64},"MRD status can change longitudinally, shifting between MRD positive and MRD negative. The review notes that sustained MRD negativity is associated with better outcomes, while loss of MRD negativity relates to disease progression.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence and challenges surround using MRD dynamics to guide everyday treatment decisions?",{"text":72,"@type":64},"The review discusses evidence from the literature supporting MRD-guided decision-making and highlights major concerns that must be addressed before implementing MRD-dynamics monitoring in routine clinical practice. It also emphasizes the need for highly sensitive testing methods.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345018,1790197810,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Targeted Oncology (2026) 21:167–186  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1523-026-01199-z  \nEvidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma  \nXinai Gan1,2,3 · Linfeng Li1,3 · Li Zhang1,3 · Yuhuan Zheng1,3 · Ting Niu1,3,4,5 · ZhengyuYu1,3  \nReceived: 18 November 2025 / Accepted: 22 January 2026 / Published online: 10 February 2026 © The Author(s) 2025, modified publication 2026  \nAbstract  \nMultiple myeloma (MM) is a heterogeneous cancer that remains incurable. After treatment, the presence of residual myeloma clonal cells, or minimal residual disease (MRD), leads to tumor recurrence (relapse) and treatment failure (refractory disease). Strong clinical evidence indicates MRD is a surrogate marker of survival in patients with MM and is of important prognostic value in disease management. MRD status is dynamic and longitudinal changes in MRD status have different clinical implications. For example, sustained MRD negativity (undetectable MRD) has been associated with greatly improved survival outcomes, whereas the loss of MRD negativity is associated with disease progression. Although research on the prognostic impact of MRD dynamics in real world clinical practice is ongoing, several major concerns remain to be addressed before implementing the monitoring of MRD dynamicsand MRD-guided therapeutic decision making in everyday clinical practice in the management of MM. In this review, we discuss the prognostic and clinical value of MRD dynamics, the evidence from literature for MRD-guided clinical decision making, and the challenges around implementing monitoring of MRD dynamics into clinical practice.  \nPlain Language Summary  \nMultiple myeloma (MM) is a type of cancer that develops in the bone marrow, in which cancerous plasma cells (or specialized white blood cells) multiply and replace the normal plasma cells that fight infections. After completing treatment, patients with MM may sometimes have minimal residual disease (MRD) or a small number of remaining cancerous plasma cells in the bone marrow, even if they show no other signs or symptoms of disease (i.e., have achieved remission). When treating MM, testing for MRD can help clinicians to predict the patient’s future risk of disease recurrence (or relapse) and may guide the decision-making process. The changes in the presence or absence of MRD over time (or MRD dynamics) are important for predicting these risks. For example, patients with undetectable cancer cells for a long period of time (i.e., sustained MRD negativity) have a much greater likelihood of survival than those in whom MRD is initially absent but cancer cells are later detected (i.e., shift from MRD-negative to MRDpositive), who are more likely to experience disease relapse or worsening. Monitoring MRD dynamics requires the use of highly sensitive testing techniques, such as next-generation sequencing, next-generation flow cytometry, and mass spectrometry. There are several questions regarding the role of monitoring MRD dynamics in predicting disease relapse and prognosis, as well as knowledge gaps around its use in routine clinical practice. Ongoing research may help to optimize the monitoring MRD dynamics to enable its widespread use and improve the management of patients with MM.  \nXinai Gan and Linfeng Li contributed equally to this work.  \n* Ting Niu [niuting@wchscu.cn](niuting@wchscu.cn)  \n* Zhengyu Yu [zhengyuyu@wchscu.cn](zhengyuyu@wchscu.cn)  \n1 Department of Hematology, West China Hospital, Sichuan University, 37 Guoxue Alley, Wuhou District, Chengdu 610041, Sichuan, China  \n2 West China School of Medicine, Sichuan University, Chengdu, China  \n3 Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China  \n4 State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China  \n5 National Facility for Translational ","cbCaismPYuR4NfDZ","https://ap.wps.com/l/cbCaismPYuR4NfDZ","pdf",1101124,"English","# Abstract\n# Plain Language Summary\n# Key Points\n# 1 Introduction","[{\"question\":\"Why is minimal residual disease (MRD) important in multiple myeloma?\",\"answer\":\"After treatment, residual myeloma clonal cells (MRD) are linked to relapse and treatment failure. MRD is described as a strong surrogate marker of survival and has important prognostic value in MM management.\"},{\"question\":\"How do MRD dynamics affect clinical interpretation over time?\",\"answer\":\"MRD status can change longitudinally, shifting between MRD positive and MRD negative. The review notes that sustained MRD negativity is associated with better outcomes, while loss of MRD negativity relates to disease progression.\"},{\"question\":\"What evidence and challenges surround using MRD dynamics to guide everyday treatment decisions?\",\"answer\":\"The review discusses evidence from the literature supporting MRD-guided decision-making and highlights major concerns that must be addressed before implementing MRD-dynamics monitoring in routine clinical practice. It also emphasizes the need for highly sensitive testing methods.\"}]","Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma | PDF",1790056239,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0061f9a5d3043881c75bdb3d39364e8.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a98b176738d3253f53763a4b6f9ea4f1.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f5cb14a63768ff7c2290674b0654bfb.webp",981,1303,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88f20986df68b6029d2de49ea12a9b67.webp",980,1301]